Pharmaceutical composition and device for treating pain
The invention relates to a system for the sequential intranasal administration of at least one active ingredient selected from a DR group having at least one side effect of respiratory depression and at least one active ingredient selected from an ADR group that counteracts the respiratory depression that may be induced by the active ingredients of the DR group. The invention also relates to a portable sequential intranasal administration device comprising an intranasal administration system according to the principles of the invention.
1. A method for sequential intranasal administration of at least one active ingredient selected from a DR group having at least one side effect of respiratory depression and at least one active ingredient selected from an ADR group that counteracts respiratory depression that may he induced by the at least one active ingredient of the DR group, the method comprising:
administering, from a first storage space, an initial dose of a first active formulation comprising the at least one active ingredient selected from the DR group, in response to an initial actuation of a portable sequential intranasal administration medical device by a patient wishing to receive pharmaceutical administration; and
after administering the initial dose, administering, from at least a second storage space, at least one subsequent dose of a second active formulation different from the first active formulation comprising the at least one active ingredient selected from the ADR group without administering the first active formulation, in response to at least one subsequent actuation of the portable sequential intranasal administration medical device by the patient wishing to receive subsequent pharmaceutical administration.
2. The method for sequential intranasal administration of claim 1 , wherein the first active formulation further comprises at least one active ingredient from the ADR group.
3. The method for sequential intranasal administration of claim 2 , wherein the at least one active ingredient from the ADR group of the first active formulation is identical to the at least one active ingredient from the ADR group of the second active formulation.
4. The method for sequential intranasal administration of claim 1 , wherein the portable sequential intranasal administration medical device comprises at least one device for measuring at least one of time or at least one biological parameter, the method further comprising measuring at least one of time or at least one biological parameter via the at least one device, wherein administering the at least one subsequent dose is based on the measured time and/or the at least one biological parameter.
5. The method for sequential intranasal administration of claim 4 , wherein the at least one device for measuring at least one of time or at least one biological parameter is configured to measure at least one of oxygen saturation or respiratory rate.
6. The method for sequential intranasal administration of claim 1 , wherein the second active formulation further comprises at least one active ingredient from the DR group.
7. The method for sequential intranasal administration of claim 6 , wherein the at least, one active ingredient from the DR group of the second active formulation is identical to the at least one active ingredient from the DR group of the first active formulation.
8. The method for sequential intranasal administration of claim 1 , wherein the at least one active ingredient from the DR group is selected from a group consisting of benzodiazepines and the least one active ingredient from the ADR group is flumazenil.
9. The method for sequential intranasal administration of claim 1 , wherein the at least one active ingredient from the DR group is sufentanil and the at least one active ingredient from the ADR group is naloxone.
10. The method for sequential intranasal administration of claim 1 , wherein the at least one active ingredient from the DR group is selected from a group consisting of opioid agonists and the at least one active ingredient from the ADR group is selected from a group consisting of opioid antagonists.